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Coronavirus-2019 (COVID-19) infection is responsible for the pandemic outbreak across the 
world. The pathophysiology of COVID-19 has been characterized by endothelial dysfunction, 
and a thromboinflammatory state. Severe infection and poor clinical outcomes have been 
associated with diffuse endothelial dysfunction and a hyperinflammatory state leading to a 
cytokine storm which further enhances thrombotic complications.[1] [2] The pathophysiology 
uniquely affects the lungs in its early stages as evidenced by autopsy reports of diffuse alveolar 
damage along with pulmonary intravascular microthrombi in the absence of known venous 
thromboembolism (VTE).[3] Multiple retrospective and prospective clinical trials have 
evaluated thromboinflammatory biomarkers linking them to poor prognosis among patients 
with COVID-19 infection.[4] [5] [6] The thrombotic biomarkers evaluated include D-dimer levels, 
fibrinogen levels, prothrombin time (PT), and activated partial thromboplastin time (aPTT). 
There have been several reports and meta-analyses linking elevated D-dimer levels with poor 
prognosis including severity and mortality with COVID-19 infection.[5] [7] However, several 
concerns have been raised with the use of D-dimer as a biomarker among COVID-19 infected 
patients. D-dimer has low specificity and elevated levels are often seen with advanced age, 
African American race, female sex, active malignancy, surgery, pregnancy, immobility, cocaine 
use, connective tissue disorders, end-stage renal disease, and prior thromboembolic disease.[8] 
Also, D-dimer reflects a later stage in the hemostatic process and is released when a clot is 
degraded by the fibrinolytic processes. Other standard laboratory tests including PT and aPTT 
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measure the clotting activity from the plasma and ignore other components of the coagulation 
such as the platelets and the fibrinolysis. The platelet count and fibrinogen concentration also 
have the caveat of providing static measures with no information regarding their functionality. 
On the other hand, whole blood viscoelastic analysis can be rapidly performed by 
thromboelastography (TEG) or rotational thromboelastometry (ROTEM), which measure the 
whole blood capability to make and sustain clot formation.[9] Several reports have now been 
published describing early experience with TEG or ROTEM for patients admitted with severe 
COVID-19 to critical care settings in Italy and the United States.[10] [11] [12] The TEG 
parameters include reaction time (R, represents the initiation phase and measures the time of 
latency from start of the test to initial fibrin formation), clot formation time (K, represents 
amplification phase and measures the time taken to achieve 20 mm of clot strength), angle or α 
(K angle, represents the propagation phase and measures the rate of clot formation), maximum 
amplitude (MA, represents the overall stability of the clot), and amplitude at 30 minutes (LY30, 
represents the fibrinolysis phase and measures the percentage decrease in amplitude at 
30 minutes post-MA). Panigada et al demonstrated a hypercoagulable profile measured by TEG 
in 24 patients admitted to the intensive care unit (ICU) with COVID-19.[10] They noted that the 
reaction time (R) and clot formation time (K) were shorter than those of the reference 
population in 50 and 83% of the COVID-19 patients, respectively. K angle and MA values were 
higher than those of the reference population in 72 and 83% of the COVID-19 patients, whereas 
clot lysis at 30 minutes (LY-30) was lower in 100% of the COVID-19 population.[10] Similar 
results were observed by Maatman et al and Wright et al, showing a COVID-19-associated 
hypercoagulable state measured by TEG and associated fibrinolysis shutdown (defined by LY-30 
<0.8%)[11] in 12 and 44 patients admitted to the ICU, respectively ([Table 1]).[11] [12] The 
patients with hypercoagulable profile and/or fibrinolysis shutdown were found to have a higher 
rate and shorter time to VTE (40 vs. 5% in patients without shutdown, p = 0.013).[12] Similarly, 
Mortus et al found high K/α or high MA in 19 out of 21 patients admitted with severe COVID-19 
when measured by TEG.[13] Finally, Pavoni et al showed consistent evidence of a 
hypercoagulable state in severe COVID-19 with the ROTEM platform with improvement of 
fibrinogen clot firmness measurements after 10 days of illness, suggesting a dynamic 
component of changes in coagulation that accompany the rise and fall of inflammatory 
parameters.[14] 
In summary, all the current studies support COVID-19 as a hypercoagulable and hypofibrinolytic 
state in the ICU setting. It should be noted that all the above-mentioned studies used the 
TEG5000 hemostasis analyzer (Haemonetics, Braintree, Massachusetts, United States) instead 
of the TEG-6S, which is a point-of-care device and did not measure fibrin clot strength.[9] Prior 
studies have shown fibrin clot strength as a strong and independent predictor of ischemic 
outcomes.[15] 
 
All intubated ICU patients with low risk of bleeding are recommended low-intensity 
pharmacologic prophylaxis including low-molecular-weight heparin (nadroparin 65 IU/kg/day, 
or dalteparin 5,000 IU/day, or enoxaparin 40 mg/day) and low-dose unfractionated heparin 
(5,000 units twice a day) for VTE prevention.[16] However, due to the very high incidence of 
thromboembolic complications despite standard low-dose VTE prophylaxis among severe 
COVID-19 infections with elevated D-dimer levels, intermediate-intensity or full-dose 
anticoagulation as opposed to standard low-intensity prophylaxis is now routinely used.[17] 
The data regarding the best biomarkers to guide decisions about intensification of 
anticoagulant prophylaxis in patients with severe COVID-19 are rapidly evolving.[17] Due to the 
ease of testing and their properties as a single test that is able to evaluate different 
components and stages of coagulation and platelet function at the bedside, TEG or ROTEM may 
be ideally suited to predict thrombotic risk in patients with moderate or severe COVID-19. 
Other advantage, especially in the setting of COVID-19, includes the flexibility of point-of-care 
testing with the newer TEG6s and ROTEM-Sigma devices, which can be safely performed 
without the risk of aerosolization. To this end, we are conducting an ongoing study—The 
evaluation of hemostasis by thromboelastography, platelet function testing, and biomarker 
analysis in hospitalized COVID-19 patients (TARGET-COVID Study)—to determine an individual 
patient's degree of thrombotic and bleeding risk using TEG. We propose that the development 
of individual thrombogenic phenotypes will help personalize antithrombotic therapy in patients 
affected by COVID-19 and improve outcomes. 
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Summary of TEG and ROTEM parameters in COVID-19 infection (data presented as mean values in 
COVID-19/reference range) 
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Abbreviations: CFT, clot formation time; CT, clotting time; K, clot formation time; LY30, amplitude at 
30 minutes; MA, maximum amplitude; MCF, maximum clot firmness; ML, maximum lysis; R, reaction 
time; ROTEM, rotational thromboelastometry; TEG, thromboelastography. 
 
 
